Isis Pharmaceuticals Bags USD 35 M Up Front in Deal with GSK
Debbie Tranter
Abstract
GSK has entered into an alliance with Isis Pharmaceuticals to pursue and develop new therapeutics against targets for rare and serious diseases.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.